The trial enrolled an estimated 378 patients who were randomized (2:1) to receive either subcutaneous pembrolizumab administered with chemotherapy or IV KEYTRUDA in combination with chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback